查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1963829

急性偏頭痛藥物市場－全球產業規模、佔有率、趨勢、機會、預測：治療方法、給藥途徑、通路、區域及競爭格局，2021-2031年

Acute Migraine Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球急性偏頭痛治療市場預計將從 2025 年的 23.2 億美元成長到 2031 年的 31.1 億美元，複合年成長率為 5.01%。

這些藥物專為偏頭痛發作初期使用而設計，可緩解疼痛及相關症狀，如噁心和光敏感性。這與預防性治療策略有所區別。市場成長的主要促進因素是全球頭痛疾病盛行率的不斷上升，以及患者迫切需要快速起效的治療方法，以便盡快恢復日常活動。此外，創新藥物類別的推出，特別是抑鈣素基因相關胜肽受體拮抗劑和地坦類藥物，也是重要的推動因素，為對傳統曲坦類藥物不耐受或無反應的患者提供了有效的治療選擇。

市場概覽
預測期 2027-2031
市場規模：2025年 23.2億美元
市場規模：2031年 31.1億美元
複合年成長率：2026-2031年 5.01%
成長最快的細分市場 醫院藥房
最大的市場 北美洲

儘管取得了這些積極進展，但仍存在許多重大障礙，例如診斷不足以及圍繞這種疾病的社會污名，這些都限制了患者獲得處方級治療的機會。由於缺乏臨床檢驗或無法獲得專業的醫療服務，許多患者被迫依賴非處方藥。根據歐洲偏頭痛和頭痛聯盟2024年的數據，74%的偏頭痛患者認為醫療專業人員沒有認真對待他們的症狀。患者與醫療服務提供者之間持續存在的這種認知差距，是推廣先進急性治療方案的主要障礙，並阻礙了整個市場的成長。

市場促進因素

新型抑鈣素基因相關胜肽 (CGRP) 受體拮抗劑和 5-HT1F促效劑的出現是推動市場成長的主要動力，從根本上改變了對標準曲坦類藥物無反應患者的治療格局。這些先進療法，包括口服吉泮和地坦，憑藉其療效和卓越的心血管安全性，填補了重要的治療空白，並在大型醫療系統中廣泛應用。這些針對特異性機制的治療方法之所以受到青睞，是因為它們能夠在緩解疼痛的同時，避免傳統治療標準中固有的血管收縮風險。領先的創新企業也反映了這項商業性成功；例如，輝瑞公司於 2024 年 10 月發布的 2024 年第三季財報顯示，其 CGRP標靶治療Nurtec ODT/Vydura 的全球營收成長了 45%，凸顯了市場對這些先進治療方法的強勁需求。

同時，全球偏頭痛發病率和盛行率的不斷上升，導致對治療方案的需求居高不下，並給公共衛生基礎設施帶來沉重負擔。龐大的患者族群亟需便捷有效的急性治療方案，以減輕偏頭痛造成的失能。根據美國國立衛生研究院 (NIH) 於 2024 年 12 月發布的《全球偏頭痛負擔趨勢》調查報告，預計全球偏頭痛患者人數將激增至約 11.6 億，其中女性受到的影響尤為顯著。如此龐大的患者需求正在推動市場成長，同時也凸顯了廣泛應用治療方法的必要性。正如艾伯維公司於 2024 年 10 月發布的《2024 年第三季財務業績報告》所示，Hubre Ruby 的全球淨銷售額達到 2.69 億美元，印證了這項由患病率上升趨勢驅動的市場擴張。

市場挑戰

偏頭痛的污名化和診斷不足嚴重阻礙了急性治療市場的成長，因為這導致患者需求與臨床干預脫節。當偏頭痛被輕描淡寫地視為輕微症狀或心理缺陷時，患者會將這些污名內化，並往往猶豫是否尋求專業醫療協助。因此，相當一部分患者依賴特異性處方藥，而這些藥物並未對處方藥市場做出貢獻。由此，諸如CGRP受體拮抗劑等先進療法的潛在市場被人為地限制，因為治療方法需要醫生的診斷。

歐洲偏頭痛與頭痛聯盟2024年的報告就是一個突出的例子，該報告指出，35%的偏頭痛患者由於「害怕尷尬或受到批評」而延遲或避免就醫。這項統計數據揭示了一個顯著的差距：由於社會和醫療方面的污名化，潛在的急性治療使用者流失。由於迴避臨床環境，這些患者實際上被排除在專業急性治療藥物的商業市場之外，直接降低了新治療層級的整體成長潛力和普及率，儘管這些療法已被證明有效。

市場趨勢

快速起效的鼻內吸入系統正成為一股重要的發展趨勢。這些系統旨在克服口服藥物治療在治療胃腸道麻痺和伴隨嚴重噁心的偏頭痛患者方面的局限性。這些創新製劑可繞過胃腸道，確保藥物穩定吸收並加速起效。這對於口服給藥無效的嚴重偏頭痛發作至關重要。該領域的一項重大進展是Dihydroergotamine鼻粉製劑STS101近期獲得監管部門批准。根據2024年11月NeurologyLive的報告“Satsuma公司重新提交STS101鼻粉的新藥申請”，ASCEND試驗的臨床數據顯示，34.2%的患者在兩小時內疼痛得到緩解，這支持了該給藥方式在改善急性治療效果方面的潛力。

同時，市場格局正在重塑，針對單藥治療效果不佳的患者，推出了曲坦類藥物和非類固醇消炎劑（NSAIDs）的固定劑量組合藥物。這些複方製劑針對不同的病理機制—抑制5-羥色胺受體並同時減輕神經發炎—從而產生協同的臨床療效和持續緩解。新型雙機制口服療法AXS-07的研發便是這項創新的最佳例證。根據Axsome Therapeutics公司2024年4月發布的公告，“新的匯總數據顯示AXS-07療效顯著”，23%的患者在服用該複方製劑兩小時內偏頭痛疼痛得到緩解，顯著高於安慰劑組的11%。這證實了這種綜合療法的臨床優勢。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：急性偏頭痛藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（預防性藥物、止痛藥）
    • 給藥途徑（口服、注射、鼻噴霧、其他）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美急性偏頭痛藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲急性偏頭痛藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區急性偏頭痛藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲急性偏頭痛藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲急性偏頭痛藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球急性偏頭痛藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Endo International PLC
  • AbbVie Inc.
  • Impax Laboratories LLC
  • Glaxo Smith Kline PLC
  • Astellas Pharma Inc
  • Amgen Inc
  • Bayer AG
  • AstraZeneca PLC
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Pfizer Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17586

The Global Acute Migraine Drugs Market is projected to expand from USD 2.32 Billion in 2025 to USD 3.11 Billion by 2031, registering a CAGR of 5.01%. These pharmaceutical interventions are specifically designed for administration at the beginning of a migraine attack to mitigate pain and associated symptoms like nausea and light sensitivity, separating them from preventive strategies. Market growth is largely underpinned by the increasing global incidence of debilitating headache disorders and the pressing need for fast-acting treatments that allow patients to resume daily activities. Furthermore, the introduction of innovative drug classes, particularly calcitonin gene-related peptide receptor antagonists and ditans, serves as a significant catalyst by offering viable options for individuals who cannot tolerate or do not respond to traditional triptan medications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.32 Billion
Market Size 2031USD 3.11 Billion
CAGR 2026-20315.01%
Fastest Growing SegmentHospital Pharmacies
Largest MarketNorth America

Despite these positive developments, the market encounters substantial obstacles stemming from the underdiagnosis and social stigma attached to the condition, which restricts access to prescription-grade therapies. Many patients depend on over-the-counter remedies because they lack clinical validation or access to specialized healthcare services. Data from the European Migraine & Headache Alliance in 2024 indicates that 74% of migraine sufferers felt medical professionals failed to take their condition seriously. This persistent disconnect between patients and healthcare providers represents a critical barrier that curtails the uptake of advanced acute treatments and hampers broader market growth.

Market Driver

The emergence of novel calcitonin gene-related peptide (CGRP) receptor antagonists and 5-HT1F agonists is a primary force accelerating market growth, fundamentally altering the treatment landscape for those who do not respond to standard triptans. These advanced pharmacotherapies, including oral gepants and ditans, fill a critical therapeutic void by delivering efficacy alongside superior cardiovascular safety profiles, encouraging widespread adoption within major healthcare systems. The transition toward these mechanism-specific treatments is fueled by their capacity to offer pain freedom without the vasoconstrictive risks inherent in older care standards. Leading innovators reflect this commercial success; for instance, Pfizer's 'Third-Quarter 2024 Earnings Release' in October 2024 reported a 45% global increase in operational revenues for its CGRP-targeted therapy, Nurtec ODT/Vydura, highlighting the strong demand for these sophisticated interventions.

Simultaneously, the increasing global incidence and prevalence of migraine disorders maintain high demand for therapeutic solutions, placing significant pressure on public health infrastructures. The magnitude of the affected population requires accessible and effective acute care options to alleviate the disability caused by the condition. According to the 'Global Trends in Migraine Burden' study by the National Institutes of Health in December 2024, global migraine cases have surged to approximately 1.16 billion, with a disproportionate impact on female individuals. This extensive patient need translates into substantial market value and underscores the requirement for widely available treatments, as evidenced by AbbVie's 'Third-Quarter 2024 Financial Results' in October 2024, which showed global net revenues for Ubrelvy reaching $269 million, confirming the sector's expansion driven by these prevalence dynamics.

Market Challenge

The stigmatization and underdiagnosis of migraine serve as major impediments to the growth of the acute drug market by disconnecting patient needs from clinical intervention. When migraine is dismissed as a minor complaint or a psychological weakness, patients frequently internalize this bias and hesitate to seek professional medical assistance. This reluctance causes a significant segment of the patient population to rely on non-specific, over-the-counter medications that do not contribute to the prescription pharmaceutical sector. As a result, the addressable market for advanced therapeutics, such as CGRP receptor antagonists, is artificially restricted since these treatments necessitate a physician's diagnosis.

Highlighting this issue, the European Migraine & Headache Alliance reported in 2024 that 35% of individuals with migraine admitted to delaying or avoiding medical advice due to embarrassment and fear of judgment. This statistic reveals a critical gap wherein potential users of acute therapies are lost to societal and medical stigma. By staying away from clinical environments, these patients are effectively removed from the commercial market for specialized acute drugs, which directly reduces the overall growth potential and adoption rates of new therapeutic classes, despite their proven efficacy.

Market Trends

The advancement of rapid-onset intranasal and inhalation delivery systems is emerging as a significant trend, specifically engineered to overcome the limitations of oral pharmacotherapy for patients experiencing migraine-associated gastroparesis and severe nausea. By bypassing the gastrointestinal tract, these innovative formulations ensure consistent drug absorption and accelerate therapeutic onset, which is crucial for debilitating attacks where oral administration proves ineffective. A key development in this area is the progress of STS101, a dihydroergotamine nasal powder that recently navigated regulatory steps; according to a November 2024 NeurologyLive report titled 'Satsuma Resubmits NDA Over STS101 Nasal Powder,' clinical data from the ASCEND trial showed that 34.2% of patients achieved pain freedom within two hours, underscoring the potential of this delivery method to enhance acute outcomes.

Concurrently, the market is being reshaped by the introduction of fixed-dose combination therapies that merge triptans with NSAIDs to provide multimodal mechanisms of action for patients with insufficient responses to monotherapy. These unified formulations target distinct pathogenic pathways-inhibiting serotonin receptors while simultaneously reducing neuroinflammation-to yield synergistic clinical benefits and sustained relief. This innovation is best illustrated by the development of AXS-07, a novel dual-mechanism oral therapeutic; as announced by Axsome Therapeutics in April 2024 under 'New Pooled Data Highlights Efficacy of AXS-07,' the combination treatment enabled 23% of patients to achieve freedom from migraine pain at two hours compared to 11% in the placebo group, confirming the clinical superiority of this integrated approach.

Key Market Players

  • Endo International PLC
  • AbbVie Inc.
  • Impax Laboratories LLC
  • Glaxo Smith Kline PLC
  • Astellas Pharma Inc
  • Amgen Inc
  • Bayer AG
  • AstraZeneca PLC
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Pfizer Inc

Report Scope

In this report, the Global Acute Migraine Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Migraine Drugs Market, By Treatment

  • Preventive
  • Pain Relieving

Acute Migraine Drugs Market, By Route of Administration

  • Oral
  • Injectable
  • Nasal Sprays
  • Others

Acute Migraine Drugs Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Acute Migraine Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acute Migraine Drugs Market.

Available Customizations:

Global Acute Migraine Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acute Migraine Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Preventive, Pain Relieving)
    • 5.2.2. By Route of Administration (Oral, Injectable, Nasal Sprays, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Acute Migraine Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Acute Migraine Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Acute Migraine Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Acute Migraine Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Acute Migraine Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Acute Migraine Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Acute Migraine Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Acute Migraine Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Acute Migraine Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Acute Migraine Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Acute Migraine Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Acute Migraine Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Acute Migraine Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Acute Migraine Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Acute Migraine Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Acute Migraine Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Acute Migraine Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Acute Migraine Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Acute Migraine Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Acute Migraine Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Acute Migraine Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Acute Migraine Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Acute Migraine Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Acute Migraine Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Acute Migraine Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Endo International PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AbbVie Inc.
  • 15.3. Impax Laboratories LLC
  • 15.4. Glaxo Smith Kline PLC
  • 15.5. Astellas Pharma Inc
  • 15.6. Amgen Inc
  • 15.7. Bayer AG
  • 15.8. AstraZeneca PLC
  • 15.9. Dr. Reddy's Laboratories Ltd
  • 15.10. Eli Lilly and Company
  • 15.11. Pfizer Inc

16. Strategic Recommendations

17. About Us & Disclaimer